Cytosorbents Corporation (CTSO) Earnings History
Annual and quarterly earnings data from 2005 to 2024
Loading earnings history...
CTSO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CTSO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 70.6% | -47.2% | -58.2% |
| 2023 | 70.6% | -102.8% | -94.1% |
| 2022 | 59.8% | -90.9% | -94.6% |
| 2021 | 72.5% | -56.7% | -61.2% |
| 2020 | 72.0% | -26.3% | -19.9% |
Download Data
Export CTSO earnings history in CSV or JSON format
Free sign-in required to download data
Cytosorbents Corporation (CTSO) Earnings Overview
As of May 8, 2026, Cytosorbents Corporation (CTSO) reported trailing twelve-month net income of -$10M, reflecting +41.5% year-over-year growth. The company earned $-0.15 per diluted share over the past four quarters, with a net profit margin of -58.2%.
Looking at the long-term picture, CTSO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$80,000 in fiscal 2005.
Cytosorbents Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NVCR (-$173M net income, -20.8% margin), MASI ($76M net income, -9.9% margin), ICUI ($47M net income, 0.0% margin), CTSO has room to improve margins relative to the peer group. Compare CTSO vs NVCR →
CTSO Earnings vs Peers
Earnings metrics vs comparable public companies
CTSO Historical Earnings Data (2005–2024)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$21M | +29.2% | -$17M | $-0.38 | -58.2% | -47.2% |
| 2023 | -$29M | +10.9% | -$32M | $-0.65 | -94.1% | -102.8% |
| 2022 | -$33M | -33.6% | -$32M | $-0.75 | -94.6% | -90.9% |
| 2021 | -$25M | -213.4% | -$23M | $-0.57 | -61.2% | -56.7% |
| 2020 | -$8M | +59.3% | -$10M | $-0.20 | -19.9% | -26.3% |
| 2019 | -$19M | -11.9% | -$19M | $-0.60 | -84.6% | -83.3% |
| 2018 | -$17M | -103.4% | -$16M | $-0.56 | -85.0% | -77.0% |
| 2017 | -$8M | +29.1% | -$10M | $-0.31 | -63.2% | -73.6% |
| 2016 | -$12M | -46.8% | -$11M | $-0.47 | -145.5% | -140.0% |
| 2015 | -$8M | +12.8% | -$9M | $-0.33 | -200.5% | -229.4% |
See CTSO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTSO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTSO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTSO — Frequently Asked Questions
Quick answers to the most common questions about buying CTSO stock.
Is CTSO growing earnings?
CTSO EPS is $-0.15, with earnings growth accelerating to +41.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-10M.
What are CTSO's profit margins?
Cytosorbents Corporation net margin is -58.2%, with operating margin at -47.2%. Below-average margins reflect competitive or cost pressures.
How consistent are CTSO's earnings?
CTSO earnings data spans 2005-2024. The accelerating earnings trend is +41.5% YoY. Historical data enables comparison across business cycles.